Videos

Key opinion leaders in neurology discuss the safety and efficacy of apomorphine hydrochloride and provide insights into the advantages and disadvantages of its subcutaneous formulation.

Laxman Bahroo, DO and Mindy K. Bixby, DO define OFF episodes in Parkinson’s Disease and discuss how they are often unpredictable and variable in their severity.

Jill Dehlin, RN, a patient with migraine, talks about her experience receiving a subcutaneous injectable CGRP inhibitor, and neurologist Jessica Ailani, MD, explains what she counsels her patients on when prescribing a newer injectable treatment. 

Jessica Ailani, MD, a neurologist from MedStar Health, shares insight on best practices for dosing therapies used to treat migraine and implications for combining drugs together.

The assistant professor of neurology at Thomas Jefferson University discussed the potential and feasibility of brain implants in patients with stroke.

The senior director of patient management, care, and rehabilitation research at the National MS Society discussed symptoms of progressive MS that need more attention and research.

Tanuja Chitnis, MD reviews the 2018 AAN guidelines on disease-modifying therapies and discusses goals of therapy when selecting first-line treatments and monitoring response in pediatric multiple sclerosis.

Experts in multiple sclerosis discuss the importance of a multidisciplinary approach for pediatric patients and emphasize the role of social workers, psychologists, and support groups for patients and families.  

Expert neurologists discuss the variability of signs and symptoms as well as other factors to consider when diagnosing patients with amyotrophic lateral sclerosis (ALS).

A panel of key opinion leaders in neurology provides an overview of the prevalence of amyotrophic lateral sclerosis (ALS) and discusses potential causes and risk factors.

The postdoctoral researcher at Columbia University discussed the use of the DISCO-MS survey and its potential for future research projects.

The director and founder of the Sleep Centers of Middle Tennessee discussed the OSAinHome program that his practice has developed.

Richard describes the journey of his diagnosis with multiple sclerosis.

The professor of neurology at Johns Hopkins University, and a member of the Curing Coma Campaign’s Scientific Steering Committee spoke to the current limitations of clinical trials in coma.

The consultant in the Department of Neurology at Mayo Clinic discussed the advancements of Parkinson disease knowledge and treatment over the past 2 decades.

The professor of health science at the Medical University of South Carolina spoke to the dire need for more therapeutic approaches to treat some of the most difficult symptoms of dementia.

Neurology News Network for the week ending April 10, 2021.

The duo from the National Institutes of Health discussed how monitoring and treating paramagnetic rim lesions can improve patient care in multiple sclerosis.

The use of mass spectrometry is the gold standard in amyloid proteins.

Various types of biopsies to diagnosis hereditary ATTR amyloidosis are discussed.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine detailed the reasons behind the lack of research on social determinants of health on stroke outcomes.

The professor of neurology at Johns Hopkins University, and a member of the Curing Coma Campaign’s Scientific Steering Committee shared her insight into the current management of coma and the need for better prognostication.

The consultant in the Department of Neurology at Mayo Clinic discussed the mounting number of unmet needs for patients with Parkinson disease.

Experts in the field of multiple sclerosis discuss patient selection for drugs based on disease activity.

Kristen Krysko, MD, summarizes the results of the phase III ORATORIO trial and discusses the rationale for using ocrelizumab for the treatment of progressive multiple sclerosis.  

The senior director of patient management, care, and rehabilitation research at the National MS Society discussed the lack of studies on progressive MS compared to RRMS.

Variables that neurologists and other healthcare professionals need to consider when selecting an appropriate prescription therapy for migraine, and recommendations by a patient advocate on staying adherent to therapy and predicting attacks.

Limitations, in terms of safety and efficacy, of older conventional therapies used to treat migraine.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine provided plans of action to reduce racial and ethnic disparities in stroke.

The PhD candidate at the Barts MS Center in London discussed the upcoming Chariot MS study as well as further research she would like to conduct in personalized cladribine dosing.